Bharat Biotech's Covaxin- a vaccine against Covid-19 wasgiven approval by Drugs and Controller General of India (DCGI) for restricteduse in emergency situations. It has proven to be safe and triggers immuneresponse in a small group of people between 18-55 years age, as per the study publishedin TheLancet medical journal.
The use of Covaxin has been allowed under "clinicaltrial mode." As per the consent letter of the vaccine, the"COVAXINTM" has been permittedin public interest for restricted use in emergency situations.
According to a report published in Reuters, BharatBiotech's vaccine is being tested on separate 25, 800 person trial sinceNovember. Bharat Biotech said, 13,000 people participating in the late-stage oftrial has been given the second dose.
It is the interim data published in the journal thatincluded three different vaccine formulations and a placebo group among 375adults. Two formulations termed COVAXIN have been taken for more advanced stageof testing and further efficacy trials are warranted, the report said.